Literature DB >> 25027839

(1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery.

Paloma Mora1, Carles Majós, Sara Castañer, Juan J Sánchez, Andreu Gabarrós, Amadeo Muntané, Carles Aguilera, Carles Arús.   

Abstract

OBJECTIVES: To assess whether (1)H-MRS may be useful to reinforce the radiological suspicion of PCNSL.
METHODS: In this retrospective study, we included 546 patients with untreated brain tumours in which single-voxel spectroscopy at TE 30 ms and 136 ms had been performed. The patients were split into two subgroups: "training set" and "test set." Differences between PCNSL and five other types of intracranial tumours were assessed in the test set of patients using the Mann-Whitney U nonparametric test and cut-off values for pair-wise comparisons defined by constructing receiver operating characteristic curves. These thresholds were used to construct classifiers for binary comparison between PCNSL and non-PCNSL. The performance of the obtained classifiers was assessed in the independent test set of patients.
RESULTS: Significant differences were found between PCNSL and the other groups evaluated. All bilateral comparisons performed in the test set obtained accuracy values above 70 % (71-89 %). Lipids were found to be useful to discriminate between PCNSL and glioblastoma/metastasis at short TE. Myo-inositol resonance was found to be very consistent for discriminating between PCNSL and astrocytomas at short TE.
CONCLUSIONS: (1)H-MRS is useful to reinforce diagnostic suspicion of PCNSL on MRI. KEY POINTS: • (1) H-MRS can be used to reinforce the diagnostic suspicion of PCNSL. • Lipids can be used to discriminate between PCNSL and GB/MET. • Myo-inositol resonance can be used to discriminate between PCNSL and astrocytomas.

Entities:  

Mesh:

Year:  2014        PMID: 25027839     DOI: 10.1007/s00330-014-3308-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Receiver operating characteristic curves and their use in radiology.

Authors:  Nancy A Obuchowski
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

2.  Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.

Authors:  C Majós; J Bruna; M Julià-Sapé; M Cos; A Camins; M Gil; J J Acebes; C Aguilera; C Arús
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

3.  Automated classification of human brain tumours by neural network analysis using in vivo 1H magnetic resonance spectroscopic metabolite phenotypes.

Authors:  J P Usenius; S Tuohimetsä; P Vainio; M Ala-Korpela; Y Hiltunen; R A Kauppinen
Journal:  Neuroreport       Date:  1996-07-08       Impact factor: 1.837

4.  Brain lymphoma: usefulness of the magnetic resonance spectroscopy.

Authors:  Sophie Taillibert; Rémy Guillevin; Carole Menuel; Marc Sanson; Khê Hoang-Xuan; Jacques Chiras; Hugues Duffau
Journal:  J Neurooncol       Date:  2007-09-04       Impact factor: 4.130

Review 5.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

6.  Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas.

Authors:  C Majós; J Alonso; C Aguilera; M Serrallonga; S Coll; J J Acebes; C Arús; J Gili
Journal:  Neuroradiology       Date:  2003-02-19       Impact factor: 2.804

7.  Chemotherapy in newly diagnosed primary central nervous system lymphoma.

Authors:  Nooshin Hashemi-Sadraei; David M Peereboom
Journal:  Ther Adv Med Oncol       Date:  2010-07       Impact factor: 8.168

8.  Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy.

Authors:  Inga Harting; Marius Hartmann; Gregor Jost; Clemens Sommer; Rezvan Ahmadi; Sabine Heiland; Klaus Sartor
Journal:  Neurosci Lett       Date:  2003-05-22       Impact factor: 3.046

9.  Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.

Authors:  S-S Lu; S J Kim; H S Kim; C G Choi; Y-M Lim; E J Kim; D Y Kim; S H Cho
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-08       Impact factor: 3.825

10.  CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003.

Authors:  I S Haldorsen; J Kråkenes; B K Krossnes; O Mella; A Espeland
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-22       Impact factor: 3.825

View more
  5 in total

1.  Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma.

Authors:  Hiroaki Nagashima; Takashi Sasayama; Kazuhiro Tanaka; Katsusuke Kyotani; Naoko Sato; Masahiro Maeyama; Masaaki Kohta; Junichi Sakata; Yusuke Yamamoto; Kohkichi Hosoda; Tomoo Itoh; Ryohei Sasaki; Eiji Kohmura
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

2.  Primary Central Nervous System Lymphoma.

Authors:  Yan-Hong Dong; Zhen-Jie Teng; Ming Hu; Ci Wei; Ying-Min Chen; Huan-Fen Zhao; Shu-Qian Zhang; Pei-Yuan Lyu
Journal:  Chin Med J (Engl)       Date:  2016-03-05       Impact factor: 2.628

3.  Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice.

Authors:  S C Thust; S Heiland; A Falini; H R Jäger; A D Waldman; P C Sundgren; C Godi; V K Katsaros; A Ramos; N Bargallo; M W Vernooij; T Yousry; M Bendszus; M Smits
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

4.  The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting.

Authors:  Jussi Hellström; Romina Romanos Zapata; Sylwia Libard; Johan Wikström; Francisco Ortiz-Nieto; Irina Alafuzoff; Raili Raininko
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

5.  Lymphomatosis cerebri: a rare variant of primary central nervous system lymphoma and MR imaging features.

Authors:  Hui Yu; Bo Gao; Jing Liu; Yong-Cheng Yu; Mark S Shiroishi; Ming-Ming Huang; Wen-Xiu Yang; Zhi-Zhong Guan
Journal:  Cancer Imaging       Date:  2017-10-05       Impact factor: 5.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.